Acadia Pharma (ACAD) Tops Q1 EPS by 11c
Tweet
Share
E-mail
Get Alerts ACAD Hot Sheet
Price: $22.60 +2.31%
Revenue Growth %: +12.1%
Financial Fact:
Collaborative revenues: 5.27M
Today's EPS Names:
CBRS, MAYS, CRMT, More
Revenue Growth %: +12.1%
Financial Fact:
Collaborative revenues: 5.27M
Today's EPS Names:
CBRS, MAYS, CRMT, More
Join SI Premium – FREE
Acadia Pharma (NASDAQ: ACAD) reported Q1 EPS of ($0.42), $0.11 better than the analyst estimate of ($0.53). Revenue for the quarter came in at $106.6 million versus the consensus estimate of $111.63 million.
Reiterating FY21 net sales guidance of $510 to $550 million.
For earnings history and earnings-related data on Acadia Pharma (ACAD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- KeyBanc Upgrades Nucor (NUE) to Overweight
- FedEx (FDX) Tops Q4 EPS by 39c, Beats on Revenue; Offers FY27 EPS Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
